SCHEMBL481099

SCHEMBL481099

CC(=O)c1ccc(OCc2cccc(Cc3cccc(C(=O)O)c3)c2)c(Cl)c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 16/20 0.61
SMN1; SMN2 Q16637 3/20 0.54
NPC1 O15118 2/20 0.54
TP53 P04637 2/20 0.54
XBP1 P17861 2/20 0.54
RAB9A P51151 2/20 0.54
MEN1 O00255 1/20 0.54
MITF O75030 1/20 0.54
HPGD P15428 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
KMT2A Q03164 1/20 0.54
RELA Q04206 1/20 0.54
MAPT P10636 2/20 0.53
HTT P42858 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CLCN2 P51788 1/20 0.53
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
TDP1 Q9NUW8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL481438 0.95 MRGPRX4 (0.57) MRGPRX4SMN1; SMN2NPC1TP53XBP1
SCHEMBL481411 0.93 MRGPRX4 (0.54) MRGPRX4SMN1; SMN2NPC1TP53XBP1
SCHEMBL481630 0.88 MAPT (0.68) MRGPRX4SMN1; SMN2MAPTCYP2C9CYP2C19
SCHEMBL481454 0.85 MRGPRX4 (0.54) MRGPRX4SMN1; SMN2NPC1TP53XBP1
SCHEMBL481243 0.84 MRGPRX4 (0.55) MRGPRX4SMN1; SMN2NPC1TP53XBP1
SCHEMBL481005 0.84 CYSLTR1 (0.68) MRGPRX4
SCHEMBL480928 0.83 SMN1; SMN2 (0.53) MRGPRX4SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL481419 0.83 MRGPRX4 (0.46) MRGPRX4SMN1; SMN2NPC1TP53XBP1
SCHEMBL481097 0.83 MRGPRX4 (0.46) MRGPRX4SMN1; SMN2NPC1TP53XBP1
SCHEMBL481209 0.83 MAPT (0.70) MRGPRX4SMN1; SMN2MAPTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 EP disclosed
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 EP disclosed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 EP disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 MRGPRX4 193/4885SMN1; SMN2 4205/4885NPC1 1656/4885
US-20090318481-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 MRGPRX4 99/4885SMN1; SMN2 3201/4885NPC1 1477/4885
US-20090318483-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 MRGPRX4 99/4885SMN1; SMN2 3201/4885NPC1 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.